Form 4 for GILD Gilead Sciences
Accepted 2023-03-13 00:00:00 ET · period of report 2023-03-10 · accession 0001127602-23-009982 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-13 | 2023-03-10 | GILD | Mercier Johanna | Chief Commercial Off | M - OptEx | — | +11.0K | 79.4K | +16% | — |
| D | 2023-03-13 | 2023-03-10 | GILD | Mercier Johanna | Chief Commercial Off | F - Tax | $79.50 | -5,116 | 82.2K | -6% | -$406.7K |
| DM | 2023-03-13 | 2023-03-10 | GILD | Mercier Johanna | Chief Commercial Off | M - OptEx | — | -11.0K | 39.3K | -22% | — |
| DM | 2023-03-13 | 2023-03-10 | GILD | Mercier Johanna | Chief Commercial Off | A - Grant | $0.00 | +90.9K | 55.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-10 | M | A | 7,951 | — | 87,341 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2023-03-10 | M | A | 3,025 | — | 79,390 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 3 | Common | Common Stock | 2023-03-10 | F | D | 5,116 | $79.50 | 82,225 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2023-03-10 | M | D | 3,025 | — | 47,283 | D | — · — to — | 3,025 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2023-03-10 | A | A | 74,565 | $0.00 | 74,565 | D | $79.50 · — to 2033-03-10 | 74,565 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Restricted Stock Unit | 2023-03-10 | M | D | 7,951 | — | 39,332 | D | — · — to — | 7,951 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2023-03-10 | A | A | 16,350 | — | 55,682 | D | — · — to — | 16,350 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |